Aging-related matrix metallopeptidase 10 and osteopontin levels are associated with pathology, cognitive decline and age at onset in Alzheimer's disease
Ng, B.; Kodosaki, E.; Veleva, E.; Keshavan, A.; Schott, J. M.; Heslegrave, A. J.; Fox, N. C.; Zetterberg, H.
Show abstract
INTRODUCTIONAging is the strongest risk factor for Alzheimers disease (AD) characterized by amyloid-{beta} (A{beta}) plaques and tau tangles in the brain. We aim to compare biological aging-related biomarkers among AD, non-neurodegenerative control (NDC) and non-AD neurodegenerative disease (Non-AD) individuals to evaluate their clinical utility. METHODSWe included 137 participants (37 NDC, 67 AD, 33 Non-AD) from the UCL Dementia Research Centre and measured matrix metallopeptidase 10 (MMP-10), osteopontin (OPN), neurofilament-light, and glial fibrillary acidic protein in cerebrospinal fluid (CSF) samples in addition to A{beta}/pTau and clinical parameters. RESULTSElevated MMP-10 associated with poorer cognition and later onset specifically in AD, whereas elevated OPN associated with CSF A{beta} and tau pathology. MMP-10 and OPN levels improved the differentiation of AD from NDC, and AD from Non-AD, respectively. DISCUSSIONOur study provides evidence on potential clinical utility of CSF MMP-10 and OPN in AD diagnosis and supports taking biological aging into consideration in AD research.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort 97%
- Early Syndecan-4 Upregulation Predicts Cognitive and Pathological Trajectories in Alzheimer Disease 96%
- Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease 96%
Similar papers in this journal
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 96%
- Delayed primacy recall performance predicts post mortem Alzheimers disease pathology from unimpaired ante mortem cognitive baseline 96%
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum 95%
Similar papers in this journal
- Differences between plasma and CSF p-tau181 and p-tau231 in early Alzheimer’s disease 97%
- Alzheimer Disease Neuropathological Comorbidities Are Common in the Younger-Old 96%
- The Association of Alzheimer’s Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa 96%
Similar papers in this journal
- Progression of fiber bundle damage in amnestic Alzheimer's disease and LATE: a 2-year fixel-based study 96%
- A Compound Enhancing Lysosomal Function Reduces Tau Pathology, Microglial Reactivity and Rescues Working Memory in 3xTg AD Mice 95%
- Inter- and intra-chromosomal modulators of the APOE ε2 and ε4 effects on the Alzheimer’s disease risk 94%